Septerna, Inc.
NASDAQ:SEPNBiotechnology
-$0.73 today
- Market cap
- $1.88B
- Beta
- 2.38
- P/E (TTM)
- -43.6
- EPS (TTM)
- -$0.81
Volume 0.30M
Average 0.32M
SEPN Total Liabilities
Everything the company owes to creditors and other parties.
Septerna, Inc.NASDAQ: SEPN
Total Liabilities · Q3 FY2026 · quarter ended Sep 2026
Total liabilities falls 12.1% from a year ago
Total liabilities stood at $191.48M at the end of Q3 FY2026, down 12.1% from a year earlier and up 6.4% from the prior quarter. Over 3 fiscal years it compounded at +38.7% a year.
Context
- Total liabilities amounted to 30.9% of total assets at the end of Q3 FY2026, down 5.0 pp from a year earlier.
- Total liabilities increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether total liabilities keeps falling in the next quarterly balance sheet after a -12.1% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 214.26M USD
- Year-over-year change
- +486.9%
- 3-year CAGR
- +38.7%
| Period | Period end | Total Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 214.26M | +486.9% |
| FY2024 | 2024-12-31 | 36.51M | -78.4% |
| FY2023 | 2023-12-31 | 169.24M | +110.7% |
| FY2022 | 2022-12-31 | 80.32M | — |
Total Liabilities vs competitors
How SEPN compares with its peers on the latest reported figures
- SEPN's Sep 2026 total liabilities of $191.48M is the highest of the 7 companies compared; the peer median is $49.34M.
- Its year-over-year change of -12.1% is the 5th highest of 6, against a peer median of +60.1%.
- Total liabilities amounts to 30.9% of total assets for SEPN, versus a peer median of 8.3%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
SEPNSepterna, Inc. | Sep 2026 | $191.48M | -12.1% | +38.7% | 30.9% |
KLRAKailera Therapeutics, Inc. | Jun 2026 | $92.95M | — | — | 7.7% |
| Mar 2026 | $78.01M | +91.3% | -4.6% | 18.6% | |
| Jun 2026 | $71.01M | +60.1% | -31.8% | 5.0% | |
MBXMBX Biosciences, Inc. Common Stock | Sep 2026 | $27.67M | +120.7% | -43.4% | 5.5% |
| Mar 2026 | $27.67M | +5.1% | +11.8% | 59.6% | |
| Mar 2026 | $8.85M | -61.7% | -2.4% | 9.0% | |
| Peer median (excluding SEPN) | $49.34M | +60.1% | -4.6% | 8.3% | |
Competitors are the stored peer set for SEPN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Septerna, Inc.
NASDAQ:SEPN
Intrinsic Alpha fair value
Locked
Current Price
$39.45
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.